The FDA has approved Roche’s subcutaneous injection for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

A study comparing pelvic floor yoga and general exercise found both effective in reducing urinary incontinence in women, with no significant difference between the two approaches.

Adding allopurinol to maintenance therapy for paediatric ALL improves outcomes and reduces liver toxicity, even in patients with normal 6-MP metabolism.

A study from Weill Cornell Medicine, New York, USA has revealed a unique pattern of brain activity that may predispose certain individuals to depression.

A groundbreaking clinical trial testing QH104, an allogeneic B7H3-targeting CAR-γδT cell therapy, has shown promising results for patients with recurrent glioblastoma.

A new study provides the first evidence that breastfeeding is safe for women with BRCA mutations after breast cancer treatment.

Results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study have been presented at ESMO 2024, Barcelona, Spain

The PEACE-3 trial shows that combining Enzalutamide with Radium-223 improves progression-free survival in metastatic castration-resistant prostate cancer.

A study revealed that the severity of Raynaud’s phenomenon, a common early manifestation of systemic sclerosis, is influenced significantly by ambient temperature.

New clinical trial results, presented at ESMO 2024, show that an investigational mRNA-based vaccine CVGBM is safe and well-tolerated in patient with newly diagnosed MGMT-unmethylated glioblastoma (GBM).